Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin Predictions are Best-in-Class and Identify when Patients have been Misdiagnosed
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) has published a groundbreaking study on its enhanced Caris GPSai™ platform in AACR's Cancer Research Communications Journal. The deep learning AI system, trained on over 200,000 cases, demonstrates exceptional accuracy in identifying tumor tissue origin, achieving 95.0% accuracy in non-CUP cases.
The system successfully identified tissue origin in 84.0% of CUP and 96.3% of non-CUP cases during validation across 97,820 cases. In clinical use, GPSai led to diagnosis changes in 704 patients, with 86.1% of cases impacting treatment eligibility based on Level 1 clinical evidence. Notably, 53.6% of surveyed physicians modified treatment plans based on these findings.
Positive
- Achieved 95.0% accuracy in identifying tumor tissue origin in non-CUP cases
- Successfully identified tissue origin in 84.0% of CUP and 96.3% of non-CUP cases
- Changed diagnosis in 704 patients with 86.1% impact on treatment eligibility
- 53.6% of surveyed physicians changed treatment plans based on findings
- Platform trained on extensive dataset of over 200,000 cases
Negative
- None.
News Market Reaction
On the day this news was published, CAI gained 2.75%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Caris GPSai™ utilizes deep learning to significantly improve diagnostic accuracy for cancers of unknown primary and misclassified tumors
This latest advancement marks a shift from traditional machine learning to a deep learning-based approach, enabling more precise prediction of tumor tissue of origin and the identification of potential misdiagnoses during routine molecular profiling, ultimately supporting more informed treatment decisions and potentially improving patient outcomes.
The enhanced Caris GPSai was trained on WES/WTS data from over 200,000 Caris-profiled cases and classifies tumors into 90 categories. The tool demonstrated
"The latest version of GPSai, which is a part of Caris' comprehensive molecular profiling platform, represents a major advancement in precision oncology," said Matthew Oberley, MD, PhD, Caris SVP and Chief Clinical Officer and Pathologist-in-Chief. "By leveraging deep learning and whole exome and whole transcriptome sequencing, GPSai enhances diagnostic confidence, enabling more accurate identification of primary tumor sites and supporting more personalized treatment decisions, without the need for additional tissue samples."
In clinical use over eight months, GPSai changed the diagnosis in 704 patients, supported by orthogonal evidence such as imaging and molecular markers. These diagnostic shifts impacted treatment eligibility in
"By enhancing diagnostic accuracy, GPSai empowers physicians to make more informed treatment decisions and identify the tumor type for patients with CUP and those that have been misdiagnosed," said David Spetzler, MS, PhD, MBA, President of Caris. "For example, we had a case where we found a woman diagnosed with triple negative breast cancer, who actually had B-cell Lymphoma; getting the correct diagnosis had a profound effect on her life."
The publication can be viewed in its entirety on the Caris Life Sciences website.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in
Forward Looking Statements
This press release contains forward-looking statements, within the meaning of the federal securities laws, about Caris Life Sciences and its business. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential," "supports" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision oncology industry; future financial performance, results of operations or other operational results or metrics; development, validation and timing of future solutions; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; our compliance with laws and regulations; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in the prospectus for our initial public offering filed with the Securities and Exchange Commission on June 20, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-publishes-study-showing-its-multi-layer-ai-based-tissue-of-origin-predictions-are-best-in-class-and-identify-when-patients-have-been-misdiagnosed-302521431.html
SOURCE Caris Life Sciences
FAQ
What accuracy rate did Caris GPSai achieve in identifying tumor tissue origin?
How many patients had their diagnosis changed by Caris GPSai?
What percentage of treatment plans were affected by Caris GPSai's findings?
How large was the training dataset for Caris GPSai?
What is the main purpose of Caris GPSai technology?
